TCGA-J2-8192-01A-11R-2241-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.570
- UV_RESPONSE_DN+0.460
- ANGIOGENESIS+0.440
- KRAS_SIGNALING_UP+0.420
- HEDGEHOG_SIGNALING+0.410
- TNFA_SIGNALING_VIA_NFKB+0.410
- INFLAMMATORY_RESPONSE+0.390
- INTERFERON_GAMMA_RESPONSE+0.390
- TGF_BETA_SIGNALING+0.360
- COMPLEMENT+0.340
Top 10 suppressed
- MYC_TARGETS_V2-0.700
- E2F_TARGETS-0.640
- MYC_TARGETS_V1-0.620
- G2M_CHECKPOINT-0.560
- OXIDATIVE_PHOSPHORYLATION-0.470
- PANCREAS_BETA_CELLS-0.440
- DNA_REPAIR-0.420
- UNFOLDED_PROTEIN_RESPONSE-0.370
- MTORC1_SIGNALING-0.330
- SPERMATOGENESIS-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-EW-A1J2-01A-21R-A13Q-07 | — | A | 0.924 |
| 2 | TCGA-A2-A0T6-01A-11R-A084-07 | — | A | 0.911 |
| 3 | fd618c1b-e230-408d-aed8-4ad6df3fc4e6 | — | — | 0.907 |
| 4 | be66e85c-d70d-4073-af6a-bcee51ef3240 | — | — | 0.907 |
| 5 | TCGA-A2-A0YD-01A-11R-A109-07 | — | A | 0.905 |
| 6 | 94f6e4f5-2447-4f1f-9f36-411f1c25a172 | — | — | 0.899 |
| 7 | 2cec663c-00c8-48b5-967b-f2a53c0fb409 | — | — | 0.897 |
| 8 | TCGA-CR-7376-01A-11R-2132-07 | — | — | 0.896 |
| 9 | SRR5088836 | — | — | 0.894 |
| 10 | SRR8518425 | — | A | 0.894 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.570 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.460 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.440 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.420 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.410 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.410 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.360 | Inavolisib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.340 | Remibrutinib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.290 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.270 | Idelalisib | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.250 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |